This content is machine translated Obesity Treatment Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward Injectable GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide have redefined pharmacological obesity treatment and achieved weight loss in the range of 15 to 20% in clinical trials. Nevertheless,...…
